Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Technical Presentation (April 2019)
33 slides from Daiichi Sankyo's technical presentation, Apr 2, 2019
Slide 1: DS-1062
DS-1062 Yutaka Noguchi DS-1062 Lead Daiichi Sankyo., CO., LTD. April 2, 2019
Slide 2: Agenda
Agenda • Overview of DXd-ADC Technology • DS-8201 and U3-1402 • Trophoblast Cell-Surface Antigen 2: TROP-2 • DS-1062 Characteristics • DS1062 Preclinical data • DS1062 Phase I study 2
Slide 3: Daiichi Sankyo ADC Franchise
Daiichi Sankyo ADC Franchise As of April 2019 ADC Franchise Clinical stage Project Potential Discovery Pre-Clinical Phase 1 Pivotal study (Targeted antigen) Indications DS-8201 Breast, Gastric, 1 (HER2) CRC, NSCLC U3-1402 2 Breast, NSCLC (HER3) DS-1062 3 NSCLC , (TROP2) DS-7300 4 Solid tumors (B7-H3
Slide 4: Overview of DXd-ADC Technology
Overview of DXd-ADC Technology 4
Slide 5: Proprietary Daiichi Sankyo ADC Technology: DXd-ADC
Proprietary Daiichi Sankyo ADC Technology: DXd-ADC DXd-ADC Proprietary Drug-Linker O O O H O N O O O O N H H H Cys S N N N N N N N O H H H O O O O F O Cysteine residue H O NH Drug-Linker O N F N O Conjugation chemistry Payload (DXd) O H O The linker is connected to cysteine residue of the antibody E
Slide 6: DXd-ADC: High Drug to Antibody Ratio (DAR)
DXd-ADC: High Drug to Antibody Ratio (DAR) High drug-to antibody ratio (DAR) T-DM1 DS-8201a Antibody Trastuzumab Anti-HER2 Ab Payload Tubulin inhibitor DNA Topoisomerase I inhibitor (DM1) (Exatecan derivative) DAR 3.5 7-8 8 HIC*chart Intensity Intensity 4 6 DAR DAR HIC*, Hydrophobic interaction chro
Slide 7: DXd-ADC: Stable Drug-linker in Plasma
DXd-ADC: Stable Drug-linker in Plasma Plasma conc. of DS-8201a and Release rates of DXd from payload in monkey DS-8201a in plasma Total Ab (ADC + Ab) Concentration (ng/mL) DS-8201a (DAR8) Released payload Time (days) Source: Ogitani-Y et al., Clin. Cancer Res. 2016; 22:5097-5108 Source: Oitate-M et
Slide 8: DXd-ADC: Mode of Action (MOA) of a Bystander Effect
DXd-ADC: Mode of Action (MOA) of a Bystander Effect ADC selectively targets antigen-expressing tumors Payload is released by lysosomal enzymes into tumors Membrane-permeable free drug attacks neighboring cancer cells which is effective against heterogeneous tumors MOA of Bystander Effect HER2-
Slide 9: DS-8201 and U3-1402
DS-8201 and U3-1402 9
Slide 10: Structure and Characteristics of DS-8201a Compared to T-DM1
Structure and Characteristics of DS-8201a Compared to T-DM1 DS-8201a T-DM1 Topoisomerase I inhibitor, Tubulin inhibitor, Payload Exatecan derivative DM1 Bystander effect YES NO DAR 7-8 3.5 O O N O H N O H N O O Digestion HO NH N N N O H H H O O O NH O O N GGFG N F N DS-8201a cleavable F N O ~8 O OH
Slide 11: DS-8201a: Clinical Efficacy (5.4 or 6.4 mg/kg)
DS-8201a: Clinical Efficacy (5.4 or 6.4 mg/kg) ClinicalTrials.gov Identifier: NCT02564900 Tumor shrinkage was observed across multiple tumor types. Source: Iwata-H et al., Abstract #2501, ASCO 2018 11
Slide 12: DS-8201a: Tumor Shrinkage Over Time by Tumor Type
DS-8201a: Tumor Shrinkage Over Time by Tumor Type ClinicalTrials.gov Identifier: NCT02564900 Includes subjects who had ≥1 postbaseline scan. Dotted lines denote 20% increase and 30% reduction in tumor size, respectively. Source: Iwata-H et al., Abstract #2501, ASCO 2018 12
Slide 13: U3-1402 (Anti-HER3 ADC)
U3-1402 (Anti-HER3 ADC) HER3 is an important target for ADC Smart-Chemo Same ADC Technology HER3 Expression DAR8 In 188 screened breast cancer study patients + Patritumab Clinically validated mAb Acceptable safety & tolerability in >300 subjects Phase 1/2 study in Breast Cancer Phase 1 Phase 2 Dose
Slide 14: Clinical Efficacy of U3-1402; HER3-positive Breast Cancer
Clinical Efficacy of U3-1402; HER3-positive (measured by IHC [2+/3+]) Advanced / Unresectable or Metastatic Breast Cancer ClinicalTrials.gov Identifier: NCT02980341 Best Percentage Change 60 Percentage Change in Sum Change in Target Lesions From Baseline (%) in Sum of Diameters From 40 of Longest Di
Slide 15: Trophoblast Cell-Surface Antigen 2: TROP2
Trophoblast Cell-Surface Antigen 2: TROP2 15
Slide 16: TROP2 is an attractive target for ADC therapy
TROP2 • A 36-kDa single pass transmembrane glycoprotein • TROP2 is overexpressed in a variety of human carcinomas including lung, breast, pancreatic, cervical, ovarian, colorectal and gastric cancers Some overlap with Irinotecan indications Normal pancreas TROP2 correlates with poor prognosis (C
Slide 17: TROP2 and Poor Prognosis
TROP2 and Poor Prognosis 1. High expression of TACSTD2 correlates with poor prognosis in Invasive Ductal Breast Cancer • Exp Mol Pathol. 2013 Feb;94(1):73-8. 2. TROP2 overexpression was associated with poor OS in solid tumors • Sci Rep. 2016 Sep 20;6:33658. 3. TROP2 tended to be expressed in cases w
Slide 18: TROP2 Expression in Lung
TROP2 Expression in Lung 25% 75% NSCLC is a good indication for DS-1062 because of its high TROP2 expression in both adeno and squamous cell carcinoma Source: Inamura K et al., Oncotarget 2017; 8:28725-28735 18
Slide 19: TROP2-ADC Competitor: Immunomedics
TROP2-ADC Competitor: Immunomedics Product Stage Conjugated drug DAR Linker IMMU-132/ Proteolytic & Phase 3 SN-38 Sacituzumab 7.6 PH- dependent (TNBC) (Topo1 inhibitor) govitecan-hziy cleavage - TNBC: FDA Breakthrough Designation granted. Confirmatory Phase 3 study is on-going. Failed to win acc
Slide 20: Sacituzumab Govitecan in TNBC
Sacituzumab Govitecan in TNBC • Phase 1/2, basket design, open-label, single-group, multicenter trial involving patients with various types of advanced solid cancers who have received at least one previous therapy for metastatic disease. • Efficacy: ORR= 33.3% mPFS= 5.5mo (n=108) • Safety: The
Slide 21: Sacituzumab Govitecan in NSCLC
Sacituzumab Govitecan in NSCLC FDA Fast Track Designation Response Rate:19% Response Duration: 6.0 months Median PFS: 5.2 months Median OS: 9.5 months Journal of Clinical Oncology 35, no. 24 (August 20 2017) 2790-2797 21
Slide 22: DS-1062
DS-1062 22
Slide 23: TROP2 ADC is designed to be best in class
DS-1062 TROP2 ADC is designed to be best in class Payload O O H O H O S S N N N O S S N N N O SS Topoisomerase I O H H O H N H O S S Cys conjugation inhibitor O GGFG N F N O O HO Antibody Selective-DAR4 to Humanized anti-TROP2 protect safety margin monoclonal antibody (hIgG1) Non-selective DAR*4 Sel
Slide 24: In vitro Cell Growth Inhibitory Activity of DS-1062a
In vitro Cell Growth Inhibitory Activity of DS-1062a DS-1062a Isotype control ADC BxPC3 (TROP2 positive) Anti-TROP2 antibody DXd TROP2 expression Calu-6 (TROP2 negative) TROP2 expression DS-1062a demonstrated specific cell growth inhibitory activity to TROP2-positive cells, but not to TROP2-negative
Slide 25: Anti-Tumor Activity of DS-1062a in Xenograft Mice Models
Anti-Tumor Activity of DS-1062a in Xenograft Mice Models Vehicl DS-1062a_10 mg/kg Isotype control ADC_10 mg/kg e Calu- NCI- HCC82 Estimated tumor volume (mm3) 6 H2170 7 TROP2 TROP2 TROP2 low high high Days after tumor inoculation DS-1062a demonstrated stronger anti-tumor activity in TROP2-high tumor
Slide 26: Comparison of DS-1062 and Sacituzumab Govitecan-hziy
Comparison of DS-1062 and Sacituzumab Govitecan-hziy DS-1062a Sacituzumab Govitecan-hziy (Daiichi Sankyo) (Immunomedics) Antibody MAAP-9001a (humanized IgG1) hRS7 (humanized IgG1) Payload DXd (TopoI inhibitor) SN38 (TopoI inhibitor) DAR 4 7.6 Linker cleavage Enzymatic pH-dependent and enzymatic Huma
Slide 27: DS1062-A-J101 Study
DS1062-A-J101 Study Daiichi-Sankyo
Slide 28: DS-1062a Phase 1 Study Design
DS-1062a Phase 1 Study Design NSCLC ≥ 3rd line Dose Escalation Dose Expansion No selection based on TROP2 expression. TROP2 (IHC) is n=40 in RDE* POC examined retrospectively MTD 3~ subjects X mg/kg Assess efficacy and safety for Q3W GO/NO-GO decision Treatment on-going in 3~ subjects patients ≥ 1.0
Slide 29: Phase I Study Sites
Phase I Study Sites • IND/CTN approved: Dec2017 • First Patient Dosed: 07Feb2018 @ National Cancer Center Hospital Study Site Investigator National Cancer Center Hospital (JP) Toshio Shimizu, MD, PhD National Cancer Center Hospital East (JP) Kiyotaka Yoh, MD Virginia Cancer Specialists (US) Alexande
Slide 30: Future prospects
Future prospects 30
Slide 31: TROP2 Expression in Various Cancers
TROP2 Expression in Various Cancers Data from The Cancer Genome Atlas 31
Slide 32: DS-1062 Landscape
DS-1062 Landscape POC in NSCLC Other TROP2 Positive Cancers TNBC Pancreatic cancer NSCL Esophageal cancer C Cholangiocarcinoma Gastric cancer Colorectal cancer Bladder, Head & Neck, Ovarian cancer, Breast Cancer (HER2+, ER/PR+) Fast-to-Market in Salvage line Earlier Lines Combination Monotherapy - I
Slide 33: Take Home Message
Take Home Message TROP2 is an attractive target for DXd-ADC: • Overexpressed in a variety of cancers • Effectively internalized with binding antibody DS-1062 has great potential: • Preclinical anti-tumor efficacy and clinical evidence of Sacituzumab govitecan in TNBC • Fulfill unmet medical needs in
Daiichi Sankyo Company — Technical Presentation (April 2019) on 6ix